ReviewSmart molecules : open access2026
Engineering metal-organic framework-based smart porous nanoplatforms for targeted therapy and theranostic applications.
Review in Smart molecules : open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal-organic frameworks (MOFs) are materials that have recently emerged with the potential for various biomedical applications. Through engineering MOFs to contain various components and functionalities, they have progressed from porous materials to "smart" MOFs that can deliver payloads to cells, release the payloads in specific situations, perform certain therapies on the cells, and even perform diagnosis and therapy procedures simultaneously. This review aims to highlight the synergistic induction of ferroptosis through nanomedicine, immunotherapy, and targeted therapeutic agents for the treatment of breast and gastrointestinal (GI) malignancies. Nanotechnology-based targeted delivery systems enhance the delivery of ferroptosis-inducing agents to cancer cells while minimizing the toxicity of these agents to healthy cells. Additionally, immunotherapeutic agents enhance the immune response to cancer cells and sensitize them to ferroptotic cell death. Targeted therapeutic agents that act on the molecular regulators of ferroptosis, such as GPX4, System Xc
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.